A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP8731 in Healthy Adult Participants, Including an Assessment of a Food Effect
Latest Information Update: 15 Nov 2023
At a glance
- Drugs ASP 8731 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Astellas Pharma Global Development
Most Recent Events
- 01 Mar 2023 Status changed from active, no longer recruiting to discontinued.
- 18 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2022 Planned number of patients changed from 124 to 160.